{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:35:23Z","timestamp":1792157723543,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.medj.2026.101029","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:10:34Z","timestamp":1771517434000},"page":"101029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial"],"prefix":"10.1016","volume":"7","author":[{"given":"Fei","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Juan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lei","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Ming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Hong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Jian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Shuai","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101029_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.medj.2026.101029_bib2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Bossi","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101029_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1186\/s12967-023-04673-8","article-title":"Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect","volume":"21","author":"Siak","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.medj.2026.101029_bib6","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s11864-023-01101-3","article-title":"Recurrent\/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?","volume":"24","author":"Juarez-Vignon Whaley","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Head and Neck Cancers, Version 2. 2025."},{"key":"10.1016\/j.medj.2026.101029_bib8","unstructured":"Chinese Society of Clinical Oncology. (2024). The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma."},{"key":"10.1016\/j.medj.2026.101029_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221096214","article-title":"Current status and advances of immunotherapy in nasopharyngeal carcinoma","volume":"14","author":"Xu","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003790","article-title":"Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)","volume":"9","author":"Yang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2026.101029_bib12","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study","volume":"35","author":"Hsu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib13","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions","volume":"13","author":"Samra","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.medj.2026.101029_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/CBM-140401","article-title":"Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysis","volume":"14","author":"Ma","year":"2014","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.medj.2026.101029_bib17","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1053\/j.gastro.2021.08.054","article-title":"A Multilocus Blood-Based Assay Targeting Circulating Tumor DNA Methylation Enables Early Detection and Early Relapse Prediction of Colorectal Cancer","volume":"161","author":"Cai","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medj.2026.101029_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12003","article-title":"EGFR-rich extracellular vesicles derived from highly metastatic nasopharyngeal carcinoma cells accelerate tumour metastasis through PI3K\/AKT pathway-suppressed ROS","volume":"10","author":"Li","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.medj.2026.101029_bib19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","volume":"34","author":"Chan","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib21","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.medj.2026.101029_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110649","article-title":"Anti-EGFR therapies in nasopharyngeal carcinoma","volume":"131","author":"Chen","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.medj.2026.101029_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3892\/ol.2023.13790","article-title":"Cetuximab or nimotuzumab in combination with chemotherapy for treating recurrent\/metastatic nasopharyngeal carcinoma: A meta-analysis and systemic review","volume":"25","author":"Ni","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.medj.2026.101029_bib25","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.7150\/thno.19710","article-title":"Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up","volume":"7","author":"You","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.medj.2026.101029_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.tranon.2018.01.013","article-title":"Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma","volume":"11","author":"Wang","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1073274821989301","article-title":"Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma","volume":"28","author":"Liang","year":"2021","journal-title":"Cancer Control"},{"key":"10.1016\/j.medj.2026.101029_bib28","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2026.101029_bib29","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2026.101029_bib30","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2026.101029_bib31","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:00:38Z","timestamp":1778922038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666634026000322"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101029","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101029"}}